The ACS's mission-driven venture capital fund

BrightEdge exists to accelerate the American Cancer Society's mission for a world without cancer.

We invest in the development of life-saving therapeutics

BrightEdge invests in the most promising for-profit oncology companies bringing innovative treatments to market.

Fighting for a World Without Cancer

BrightEdge is led by a world-class team of investors, operators, and entrepreneurs to ensure the best cancer innovations are brought to market.

News

Auron Therapeutics Closes $12.75 Million Seed Financing to Develop Differentiation Therapies for Treatment of Cancers

BrightEdge participates in Auron Therapeutics seed round.

BrightEdge Announces Second Investment in Freenome, Technology Firm Focused on Early Detection for Cancer

BrightEdge Announces Second Investment in Freenome, Technology Firm Focused on Early Detection for Cancer

American Cancer Society’s BrightEdge to Invest in Checkmate Pharmaceuticals

BrightEdge participated in the Series C funding round for Checkmate Pharmaceuticals.